A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC 820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases
Latest Information Update: 16 Aug 2023
At a glance
- Drugs Sacituzumab govitecan (Primary)
- Indications Advanced breast cancer; Brain metastases; Early breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Therapeutic Use
- 21 Nov 2022 Planned End Date changed from 1 Feb 2025 to 1 Dec 2026.
- 21 Nov 2022 Planned primary completion date changed from 17 Dec 2024 to 17 Feb 2025.
- 05 Jan 2021 Status changed from not yet recruiting to recruiting.